PL2941258T3 - Kompozycje i metody leczenia nowotworów z wykorzystaniem bakterii - Google Patents

Kompozycje i metody leczenia nowotworów z wykorzystaniem bakterii

Info

Publication number
PL2941258T3
PL2941258T3 PL13818965T PL13818965T PL2941258T3 PL 2941258 T3 PL2941258 T3 PL 2941258T3 PL 13818965 T PL13818965 T PL 13818965T PL 13818965 T PL13818965 T PL 13818965T PL 2941258 T3 PL2941258 T3 PL 2941258T3
Authority
PL
Poland
Prior art keywords
bacteria
cancer
compositions
treatment
methods
Prior art date
Application number
PL13818965T
Other languages
English (en)
Inventor
Michael J. Newman
Original Assignee
Decoy Biosystems, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decoy Biosystems, Inc. filed Critical Decoy Biosystems, Inc.
Publication of PL2941258T3 publication Critical patent/PL2941258T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL13818965T 2013-01-02 2013-12-23 Kompozycje i metody leczenia nowotworów z wykorzystaniem bakterii PL2941258T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361748369P 2013-01-02 2013-01-02
EP13818965.9A EP2941258B1 (en) 2013-01-02 2013-12-23 Compositions and methods for treatment of cancer using bacteria
PCT/US2013/077441 WO2014107365A1 (en) 2013-01-02 2013-12-23 Compositions and methods for treatment of cancer using bacteria

Publications (1)

Publication Number Publication Date
PL2941258T3 true PL2941258T3 (pl) 2020-02-28

Family

ID=49943600

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13818965T PL2941258T3 (pl) 2013-01-02 2013-12-23 Kompozycje i metody leczenia nowotworów z wykorzystaniem bakterii

Country Status (16)

Country Link
US (6) US10195259B2 (pl)
EP (1) EP2941258B1 (pl)
JP (1) JP6125041B2 (pl)
KR (1) KR102214794B1 (pl)
CN (1) CN104884073B (pl)
AU (1) AU2013371454B2 (pl)
CA (1) CA2896858C (pl)
DK (1) DK2941258T3 (pl)
EA (1) EA030573B1 (pl)
ES (1) ES2759854T3 (pl)
IL (1) IL239453B (pl)
MX (1) MX368210B (pl)
PL (1) PL2941258T3 (pl)
PT (1) PT2941258T (pl)
TW (1) TWI664976B (pl)
WO (1) WO2014107365A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI664976B (zh) 2013-01-02 2019-07-11 美商迪科生物系統公司 使用細菌治療癌症之組成物和方法
WO2015153820A1 (en) * 2014-04-02 2015-10-08 Felder Mitchell S Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer
US20170231929A1 (en) * 2014-08-19 2017-08-17 National University Corporation Okayama University Method for enhancing immune cell function and method for assessing immune cell multifunctionality
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US20200282037A1 (en) * 2017-06-16 2020-09-10 Nantbio, Inc. Bacterial vaccine
JP7097438B2 (ja) 2017-07-11 2022-07-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
DK3713586T5 (da) * 2017-11-20 2024-08-26 Codex Dna Inc Vibrio sp. organismer med modificeret lipopolysaccharid
CN111902153A (zh) * 2018-01-19 2020-11-06 4D制药研究有限公司 用于治疗或预防癌症的组合疗法
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
AU2019347502A1 (en) * 2018-09-27 2021-04-22 Indaptus Therapeutics, Inc. Methods of treatment of infections using bacteria
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US20220193149A1 (en) * 2019-05-16 2022-06-23 City Of Hope Compositions and methods for targeting tumor-associated extracellular matrix components to improve drug delivery
US20220296625A1 (en) * 2019-08-29 2022-09-22 Biomedical Research Group Inc. Cancer chemotherapy supporting agent, food, and drug
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
EP3922255A1 (en) * 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN116802303A (zh) * 2020-11-09 2023-09-22 全南国立大学校产学协力团 用于预防和治疗癌症的沙门氏菌菌株及其用途
FI129784B (en) * 2021-04-27 2022-08-31 Solar Foods Oy Methods of producing microbial product
CN120359040A (zh) * 2022-11-17 2025-07-22 因达普特斯治疗有限公司 用被杀死的完整细菌治疗癌症和感染性疾病

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4842855A (en) 1980-12-19 1989-06-27 University Of Pittsburgh Antitumor process using a Brucella abortus preparation
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US5171738A (en) * 1982-10-04 1992-12-15 Toray Industries, Inc. Method of treating malignant tumors
JPH04270965A (ja) * 1990-05-18 1992-09-28 Burton W Blais オリゴペプタイド吸着担体の調製方法、及びこれを使用したリポ多糖類の検定と除去方法
US6264952B1 (en) * 1993-11-05 2001-07-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for protecting a mammalian host against infection by Brucella
EP0817647A4 (en) * 1995-03-24 2002-10-30 Promega Corp TREATMENT OF VEROTOXIN-PRODUCING ESCHERICHIA COLI
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5997881A (en) * 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
WO1998053851A1 (en) * 1997-05-28 1998-12-03 University Of Iowa Research Foundation Laft mutants of pathogenic gram-negative bacteria
WO1999013053A1 (en) 1997-09-10 1999-03-18 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
WO2001024637A1 (en) * 1999-10-04 2001-04-12 Vion Pharmaceuticals, Inc. Methods for treating solid tumors with irradiation and bacteria
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
JP2004500042A (ja) * 1999-10-04 2004-01-08 ヴァイオン　ファーマシューティカルズ、インコーポレーテッド エフェクター分子の腫瘍標的送達のための組成物および方法
CA2411944C (en) 2000-06-09 2010-12-14 Baylor College Of Medicine The combination of antimicrobial agents and bacterial interference to coat medical devices
EP1446012B1 (en) 2001-11-21 2013-07-17 The Johns Hopkins University Combination bacteriolytic therapy for the treatment of tumors
WO2003063593A1 (en) * 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
ATE459364T1 (de) 2003-10-22 2010-03-15 Univ Johns Hopkins Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren
NZ586338A (en) * 2004-06-07 2012-02-24 Qu Biolog Inc Bacterial compositions for the treatment of cancer
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8034359B2 (en) * 2004-06-07 2011-10-11 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
EP1781096B1 (en) 2004-06-29 2016-02-24 AntiCancer, Inc. Prostate cancer selective salmonella typhimurium auxotrophs
PT1984021T (pt) 2006-01-19 2016-11-02 Res Corp Tech Inc Bactérias gram-negativas não tóxicas viáveis
AU2011226697B2 (en) 2010-03-12 2015-03-12 Research Corporation Technologies Viable gram negative bacteria lacking outer membrane agonists of TLR4/MD-2
TWI664976B (zh) 2013-01-02 2019-07-11 美商迪科生物系統公司 使用細菌治療癌症之組成物和方法

Also Published As

Publication number Publication date
HK1217289A1 (en) 2017-01-06
AU2013371454B2 (en) 2019-01-03
US11045504B2 (en) 2021-06-29
US20220047649A1 (en) 2022-02-17
MX2015008606A (es) 2016-01-14
CN104884073A (zh) 2015-09-02
US20240374656A1 (en) 2024-11-14
US10052371B2 (en) 2018-08-21
US20160228523A1 (en) 2016-08-11
MX368210B (es) 2019-09-24
EA201591017A1 (ru) 2015-12-30
KR102214794B1 (ko) 2021-02-10
CA2896858A1 (en) 2014-07-10
JP2016505604A (ja) 2016-02-25
AU2013371454A1 (en) 2015-07-02
KR20150102093A (ko) 2015-09-04
CA2896858C (en) 2022-08-23
EP2941258B1 (en) 2019-09-11
TWI664976B (zh) 2019-07-11
US10195259B2 (en) 2019-02-05
PT2941258T (pt) 2019-12-12
US20140212396A1 (en) 2014-07-31
DK2941258T3 (da) 2019-12-16
WO2014107365A1 (en) 2014-07-10
TW201440779A (zh) 2014-11-01
JP6125041B2 (ja) 2017-05-10
US20190307869A1 (en) 2019-10-10
US9265804B2 (en) 2016-02-23
BR112015015832A2 (pt) 2017-07-11
IL239453B (en) 2020-03-31
US20160199422A1 (en) 2016-07-14
IL239453A0 (en) 2015-07-30
EA030573B1 (ru) 2018-08-31
ES2759854T3 (es) 2020-05-12
EP2941258A1 (en) 2015-11-11
CN104884073B (zh) 2019-07-12

Similar Documents

Publication Publication Date Title
IL273090B (en) Methods and preparations for the treatment of cancer
IL239453A0 (en) Preparations and methods for treating cancer using bacteria
GB201320723D0 (en) Composition and methods of treatment
IL245281A0 (en) Methods and preparations for the treatment of cancer
EP2958936A4 (en) METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE
SMT201700595T1 (it) Composizioni e metodi per trattare il cancro
IL238177A0 (en) Methods and preparations for the treatment of cancer
IL234678A0 (en) Diagnostic methods and preparations for cancer treatment
IL239851A0 (en) Methods and compositions for treating diseases that act to remove myelin
IL239921A0 (en) Preparations containing solutions in solid state and their use for the treatment of pain
ZA201408055B (en) Compositions and methods for the treatment of local pain
EP3004396A4 (en) Methods and compositions for the treatment of cancer
SG11201508878WA (en) Methods of treating cancer
EP3008212A4 (en) Methods of treatment of cancer
SG11201510300RA (en) Compositions and methods for treating skin
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
SG11201509596YA (en) Methods of treating cancer
GB201607581D0 (en) Treatment of cancer
ZA201509360B (en) Compositions and methods for treatment of stroke
AU2013902004A0 (en) Compositions for Therapy and Methods of Treatment
GB201322347D0 (en) Treatment of cancer
GB201318742D0 (en) Treatment of cancer
GB201308529D0 (en) Treatment of cancer
GB201305020D0 (en) Treatment of cancer
GB201322346D0 (en) Combination treatment of cancer